Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Esophagitis AND Pain

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Esophagitis AND Pain. Displaying page 1 of 1.
    EudraCT Number: 2019-002871-32 Sponsor Protocol Number: D3255C00001 Start Date*: 2020-02-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA)
    Medical condition: Eosinophilic Esophagitis (EoE)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014441-93 Sponsor Protocol Number: X-03030-3277 Start Date*: 2010-08-16
    Sponsor Name:MEDA Pharma GmbH & Co. KG
    Full Title: Clinical trial to assess the efficacy of the fixed combination product Tepilta® in the treatment of radiation-induced oesophagitis compared to its active ingredients oxetacaine and antacids, and t...
    Medical condition: Radiation-induced oesophagitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10022117 - Injury, poisoning and procedural complications 10048899 Radiation oesophagitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002288-24 Sponsor Protocol Number: Ci-FCP001 Start Date*: 2021-08-10
    Sponsor Name:Amsterdam UMC
    Full Title: Effect of citalopram on chest pain in patients with functional chest pain
    Medical condition: Chest pain can be divided in cardiac or non-cardiac chest pain (NCCP). To establish the diagnosis NCCP, acute coronary disease has to be ruled out first. NCCP can be caused by functional chest pain...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002579-33 Sponsor Protocol Number: EE-301 Start Date*: 2020-03-26
    Sponsor Name:Phathom Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophag...
    Medical condition: Erosive Esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10063657 Erosive esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-012848-16 Sponsor Protocol Number: A1501085 Start Date*: 2010-04-28
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
    Full Title: A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPH...
    Medical condition: Invasive candidiasis, including candidemia (ICC), and esophageal candidiasis (EC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10060573 Candidemia LLT
    14.1 10021881 - Infections and infestations 10064954 Invasive candidiasis LLT
    14.1 10021881 - Infections and infestations 10007161 Candidiasis of the esophagus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) HU (Prematurely Ended) SK (Completed) CZ (Prematurely Ended) BG (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000059-17 Sponsor Protocol Number: RVK28353 Start Date*: 2011-02-22
    Sponsor Name:Koege Hospital
    Full Title: The clinical significance of acid rebound: Symptoms of reflux after 8 weeks of PPI treatment in patients with functional dyspepsia.
    Medical condition: "Acid-Rebound Hypersecretion" and "Functional dyspepsia"
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10064536 Functional dyspepsia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001202-14 Sponsor Protocol Number: CiPA001 Start Date*: 2019-06-05
    Sponsor Name:Amsterdam UMC
    Full Title: CiPA Trial: Effect of Citalopram on chest pain in patients with achalasia
    Medical condition: Achalasia is a motility disorder of the esophagus. Disappearance of myenteric neurons in the esophageal wall leads to failure of relaxation of the lower esophageal sphincter (LES) and impaired peri...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000236-22 Sponsor Protocol Number: Study_protocol_CODEX-P_ver2_1 Start Date*: 2020-12-16
    Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)
    Full Title: COPD EXacerbation and Pulmonary hypertension Trial - The effect of Sildenafil treatment to patients with COPD exacerbation and pulmonary hypertension
    Medical condition: This study will investigate treatment of patients with chronic obstructive pulmonary disease (COPD), who experience frequent exacerbations (AECOPD). Only patients with a minimum of 2 moderate AECOP...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10019203 Head spinning LLT
    20.1 100000004852 10033405 Pain head LLT
    20.0 100000004852 10019218 Headache NOS LLT
    20.1 100000004856 10000460 Acid dyspepsia LLT
    22.1 100000004856 10013947 Dyspepsia aggravated LLT
    20.0 100000004856 10013948 Dyspepsia and other specified disorders of function of stomach LLT
    21.1 100000004856 10019328 Heartburn-like dyspepsia LLT
    20.1 100000004856 10064536 Functional dyspepsia LLT
    23.1 100000004856 10012727 Diarrhea LLT
    20.0 100000004859 10023222 Joint pain LLT
    21.0 100000004859 10025012 Lumbo-sacral pain LLT
    21.1 100000004859 10028322 Muscle pain LLT
    20.0 100000004856 10033394 Pain epigastric LLT
    21.1 100000004866 10016046 Facial flushing LLT
    20.0 100000004853 10013614 Double vision LLT
    21.0 100000004848 10005604 Blood in urine LLT
    20.0 100000004872 10018801 Gynecomastia LLT
    20.0 100000004872 10060603 Hematospermia LLT
    20.0 100000004851 10002272 Anemia LLT
    22.1 100000004853 10034961 Photophobia aggravated LLT
    20.0 100000004871 10023139 Jaundice NOS LLT
    20.0 100000004853 10030042 Ocular hyperemia LLT
    20.1 100000004853 10051304 Retinal bleeding LLT
    20.1 100000004853 10005889 Blurry vision LLT
    20.1 100000004856 10046272 Upper abdominal pain LLT
    20.0 100000004856 10038263 Reflux oesophagitis LLT
    20.0 100000004856 10047706 Vomiting NOS LLT
    20.0 100000004867 10016558 Fever LLT
    21.1 100000004862 10024969 Lower respiratory tract infection NOS LLT
    20.0 100000004859 10048317 Myalgia aggravated LLT
    21.1 100000004859 10003990 Back pain (without radiation) LLT
    20.1 100000004852 10020922 Hypesthesia LLT
    20.0 100000004852 10027605 Migraine NOS LLT
    21.1 100000004852 10044572 Tremor limb LLT
    20.1 100000004852 10044570 Tremor finger LLT
    20.0 100000004873 10002856 Anxiety attack LLT
    20.0 100000004873 10022442 Insomnia NOS LLT
    20.0 100000004855 10011232 Coughing LLT
    20.0 100000004862 10040756 Sinusitis NOS LLT
    20.0 100000004867 10014210 Edema LLT
    20.0 100000004867 10014211 Edema (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006074-10 Sponsor Protocol Number: MEE103219 Start Date*: 2006-06-15
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/k...
    Medical condition: Eosinophilic oesophagitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000448-26 Sponsor Protocol Number: ITOFD04-03 Start Date*: 2005-01-05
    Sponsor Name:Axcan Pharma Inc. (Axcan Pharma International BV is subsidiary of Axcan Pharma Inc.)
    Full Title: A multicentre, randomized, double-blind, placebo-controlled study of the efficacy and safety of Itopride HCl in patients suffering from functional dyspepsia
    Medical condition: Treatment of abdominal symptoms in patients with functional dyspepsia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001282-34 Sponsor Protocol Number: ITOFD04-01 Start Date*: 2005-07-30
    Sponsor Name:AXCAN PHARMA Inc.
    Full Title: A multicentre, randomized, double-blind, placebo-controlled study of the efficacy and safety of itopride HCl in patients suffering from functional dyspepsia
    Medical condition: Treatment of abdominal symptoms in patients with functional dyspepsia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004837-54 Sponsor Protocol Number: RABGRD3003 Start Date*: 2009-03-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Parallel-Group Study to Evaluate Short-Term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formul...
    Medical condition: Endoscopically proven gastroesophageal reflux disease (GERD) in a paediatric population of 1 to 11 year old subjects.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018203 GERD LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) FR (Completed) NL (Ongoing) IT (Completed) BG (Not Authorised)
    Trial results: View results
    EudraCT Number: 2016-003482-25 Sponsor Protocol Number: CICL670F2429 Start Date*: 2018-04-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A single-arm interventional Phase IV, post-authorisation study evaluating the safety of pediatric patients with transfusional hemosiderosis treated with deferasirox crushed film coated tablets
    Medical condition: Transfusional Hemosiderosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10019613 Hemosiderosis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002748-25 Sponsor Protocol Number: ICP-112-201 Start Date*: 2012-10-25
    Sponsor Name:Ironwood Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once Daily for 14 Days to Patients with Functional Dyspepsia
    Medical condition: Functional Dyspepsia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005891-15 Sponsor Protocol Number: CG104 Start Date*: 2008-05-19
    Sponsor Name:Cogentus Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symp...
    Medical condition: Gastrointestinal events including bleeding in patients receiving dual anti-platelet therapy (clopidogrel and aspirin)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018012 Gastrointestinal signs and symptoms HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Temporarily Halted) CZ (Prematurely Ended) SK (Completed) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002001-31 Sponsor Protocol Number: D9614C00004 Start Date*: 2006-10-27
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of esomeprazole once daily for the treatment of gastroesophageal reflux disease (GERD) in neonatal patients,...
    Medical condition: This prospective study will evaluate the efficacy and safety of esomeprazole for the treatment of GERD in neonatal patients.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017885 Gastrooesophageal reflux disease LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 08:10:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA